VIB: From Science to Value

Transcription

1 VIB: From Science to Value Ghent, P4EU meeting, July 4 th, Geert Van Minnebruggen

2 VIB s mission Conduct frontline life sciences research Excellence in Science and Innovation Translate results into benefits for society Excellence in Tech Transfer and Entrepreneurship

3 VIB s road to success 5 universities 1508 collaborators 66 nationalities 8 research centers 75 research groups 9 core facilities

4 VIB set-up Strong partnership with universities University campus Complementary expertise of university and VIB staff Mutual added value Share return on investment Publications: 2 affiliations IPR: joint IP (VIB in charge) Framework agreement between VIB and university

5 VIB s Management Agreement Life cycle I II III IV V Investment Government of Flanders 59 Mio EUR/Year (2017) Management agreement 5 years term ( ) Performance criteria Science Tech Transfer Communication to lay public Economy

6 VIB research budget ~130 M in % 26% Fellowships Universities VIB-grant International/ Industrial 28% 20%

7 Molecular mechanisms of life Inflammation Cancer Biology Neurobiology Molecular Neurology Medical Biotechnology Plant Systems Biology Structural Biology Microbiology VIB-KULeuven

8 Model Organisms Arabidopsis Maize Poplar Tomato Wheat Yeast Drosophila Mouse & rat Xenopus Zebrafish

9 Core Facilities BioImaging Core Bioinformatics Core Nucleomics Core Metabolomics Core Nanobody Core Protein Core Screening Core Proteomics Core Flow Cytometry NMR CryoEM

10 Results / Impact peer reviewed publications 250 breakthrough articles 63 PhDs 287 industrial agreements ; 55 patents (26 PCT s published) 1 spin-off: Aelin Therapeutics

11 36 running grants: (total 45 ERC grants + 7 POC)

12 VIB creates significant added value for society > 1200 partnerships with industry 588 patent applications 297 patents granted 253 patent families under management > M 300 industrial revenue 20 spin-offs and inward investments: +/- 1,500 jobs VIB spin-offs attracted M capital investment (>50% foreign)

13 VIB start-ups 1,2B $ total investment 823 employees AELIN THERAPEUTI

14 Economic impact of VIB

15 Interplay Science and Center of excellence Important biological questions (PI s) Stimulating environment Competitive VIB grant State of the art research infrastructure Cutting-edge equipment Disruptive technologies Expert tech profiles Dialectic environment Continuous Feedback Loop

16 Interplay Science and Credo: The boundaries of a PI s group are as good as the open access he / she has to cutting-edge infrastructures.

17 Enabling Tech Watch Core Facilities Program Technology Innovation Lab

18 Core Facilities Tech Watch Core Facilities Program Technology Innovation Lab

19 VIB Core Facilities Continuous investment in Advanced equipment & technologies Expert personnel All-in service and user lab access Fee-for-service model Co-develop the technologies of tomorrow Peer-review evaluation SAB, TEB (5y cycles)

20 Portfolio BioImaging Core Bioinformatics Core Nucleomics Core Metabolomics Core Nanobody Core Protein Core Screening Core Proteomics Core Flow Cytometry NMR CryoEM

21 The People # FTE's 2014 vs : ± 40 FTE s 2018: ± 70 FTE s GROWTH 22

22 The integrated omics approach What can happen GENOME What appears to be happening What makes it happen What has happened and is happening TRANSCRIPTOME PROTEOME METABOLOME TOOL DEVELOPMENT FUNCTIONAL STUDIES ASSAY DESIGN PHENOTYPE

23 Enabling Tech Watch Core Facilities Program Technology Innovation Lab

24 Tech Watch Team Tech Watch Team has 17 members: 3 Full time Team members 2 Core Facility Leaders 1 IP Manager 1 BD Manager 10 Group Leaders Identify and invest in new technologies that have the potential to boost research output and IP

25 Tech Watch Model VIB LABs Biotech companies Technology providers Technology Watch Advance Research High Quality Papers Intellectual Property VIB Core Facilities

26 Tech Watch Scouting Millions of companies Thousands of hits High Impact hits Papers Patents Internet Press releases ~150 companies identified / year that are communicated to VIB Technology Selection

27 Tech Watch Scope Cell Systems Biology Synthetic Biology Single Molecule Analysis Protein Imaging RNA HTS DNA Nano biotech

28 Technology Innovation Lab Embedded Technology specalists Technology Watch Innovation Lab Innovation Lab VIB Labs VIB Core Facilities Facilitate the in-house adoption of precommercial instruments by bridging the gap between early-access prototypes and commercial walk-away instruments.

29 Platform evaluations 10X Genomics Chromium ProMethION & GridION

30 Single Cell Accelerator Single Cell Accelerator Initiative is a 2 year program to invest and evaluating in emerging single cell technology platforms that will be hosted in the Innovation lab Areas of high interest include Single Cell: DNA sequencing Spatial Omics Immune profiling Methylome sequencing Pharmacogenomics CRISPR screens Culturing Extraction ATAC-seq Organoid building

31 Single Cell Accelerator Sequencing In Situ Analysis Culturing Manipulation Protein Analysis High Throughput Analysis of Single Cells: Transcriptome, Epigenome, Genome 10X Genomics, DropSeq, Fluidigm C1 Mission Bio, S2 Genomics Singulator Taraka: icell8, BD resolve, Bio-Rad, 1- CellBio, Neuroindx Spatial Charaterisation of Single Cells: Cell- Cell interactions, spatial distribution, Validation Spatial Transcriptomics, Readcoor, Genemo, Akoya Biosciences CartaNA, S2 Genomics 3D sequencing, Fluidigm Hyperion, IonPATH, Single Technologies, Spatial Genomics, Ultivue, BioSyntagma Isolation of Single Cells: Identification of rare cells, Manipulation, Culturing, Multiplex assays Cytena, Millidrop Sphere Fluidics GALT, Amberstone, Cellenion, Cell Raft, CelSee, Scaled Biolabs, Solentim, Vycap Manipulation of Single Cells and downstream anlaysis Berkeley Lights, Cytosurge, Scribe Biosciences, Celldom, HiFiBio, Inscripta, Alveole Protein analysis and immune profiling Primity Bio CITE-Seq (BioLegend, BD Genomics) Alveole, Apprise Bio, HiFiBio, MYI Diagnostics, Plexium, Protein Simple - Milo

32 Summary Tech Identification Tech Implementation Tech Offering Tech Partnering

33 Summary

34 Concluding remarks Access to cutting-edge technologies is a precondition for topnotch science anno 2018 Technology should be part of the institutional roadmap Long-term strategic financial planning is a must

35 Concluding remarks Expert dedicated technology-oriented staff is essential Funding agencies should pay more attention to infrastructure calls Partnerships will drive the future

36 Thank you.

37 The integrated omics approach GENOME TRANSCRIPTOME PROTEOME Short-read sequencing OR Long read sequencing METABOLOME PHENOTYPE MiSeq/NextSeq HiSeq/NovaSeq PacBio Sequel ONT GridION

38 The integrated omics approach GENOME TRANSCRIPTOME PROTEOME METABOLOME PHENOTYPE

39 The integrated omics approach GENOME TRANSCRIPTOME STEADY STEADY STATE METABOLISM STATE METABOLISM TRACER TRACER METABOLISM METABOLISM PROTEOME Condition Condition A ACondition Condition B B Condition Condition A ACondition Condition B B 13 C glucose 13 C glutamine other 13 C glucose 13 C glutamine other 13 C glucose 13 C glutamine other 13 C glucose 13 C glutamine other METABOLOME PHENOTYPE Sample: Sample: Tissue - body Tissue fluids (lung, - body liver, fluids blood, (lung, urine, liver, heart, blood, etc) urine, heart, etc) In vitro cell cultures In vitro (primar cell cultures y cells, (primar cancer y cells) cells, cancer cells) Tissue sections Tissue (paraffin, sections ) (paraffin, ) Sample: Sample: In vitro cell cultures In vitro (primar cell cultures y cells, (primar cancer y cells) cells, cancer cells) In vivo (mice) In vivo (mice) Output Output

40 BioImaging Core Experimental Design BioImaging Core Aquisition Analysis 41

41 Screening Core Observations Quantitative analysis Feasibility studies Assays Miniaturization Automation Screening Compounds/siRNA collections Single dose Profiling Hit compounds/known pharmaca Multiple doses, multiple repeats Building the screen Multiple read-out technologies Multi-parametric analysis High-throughput screening Liquid handling technologies Automation/integration Screening Core 42

42 Recombinant tools Expression optimization Purification & conjugation Nanobody candidates Selection & characterization Immunization Production Nanobody library generation 43

43 Beyond Borders VIB Core Facilities

44 PARTNERSHIPS